📊 CRDF Key Takeaways
Investment Thesis
Cardiff Oncology is a pre-revenue clinical-stage biotech company with severe cash burn (-$37.9M operating cash flow) and minimal revenue ($593K), indicating the company is not yet commercializing products effectively. With only 17.5 months of cash runway at current burn rates and no clear path to profitability, the company faces significant financial distress risk despite having zero debt.
CRDF Strengths
- Strong liquidity position with 3.67x current ratio providing near-term operational flexibility
- Zero long-term debt eliminates financial leverage risk and provides balance sheet flexibility
- Positive equity cushion of $45.4M provides some buffer against losses
CRDF Risks
- Severe cash burn of $37.9M annually with only $17.5M cash on hand represents critical runway risk
- Revenue of $593K is negligible and declining 13.2% YoY, indicating failed commercialization or clinical translation
- Operating losses of $49.0M and negative net margin of -7732% demonstrate unsustainable unit economics with no viable business model
Key Metrics to Watch
- Quarterly cash burn rate and cash runway remaining
- Revenue growth and drug pipeline advancement towards commercialization
- Clinical trial success rates and regulatory milestones for product candidates
CRDF Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.67x current ratio provides a solid financial cushion.
CRDF Profitability Ratios
CRDF vs Healthcare Sector
How Cardiff Oncology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CRDF Balance Sheet & Liquidity
CRDF 5-Year Financial Trend
5-Year Trend Summary: Cardiff Oncology, Inc.'s revenue has grown significantly by 87% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.95 indicates the company is currently unprofitable.
CRDF Growth Metrics (YoY)
CRDF Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $120.0K | -$10.0M | $-0.17 |
| Q2 2025 | $121.0K | -$10.0M | $-0.21 |
| Q1 2025 | $109.0K | -$10.0M | $-0.20 |
| Q3 2024 | $141.0K | -$9.7M | $-0.22 |
| Q2 2024 | $108.0K | -$10.0M | $-0.25 |
| Q1 2024 | $83.0K | -$10.0M | $-0.22 |
| Q3 2023 | $93.0K | -$8.6M | $-0.20 |
| Q2 2023 | $91.0K | -$10.4M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CRDF Capital Allocation
CRDF SEC Filings
Access official SEC EDGAR filings for Cardiff Oncology, Inc. (CIK: 0001213037)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRDF
What is the AI rating for CRDF?
Cardiff Oncology, Inc. (CRDF) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRDF's key strengths?
Strong liquidity position with 3.67x current ratio providing near-term operational flexibility. Zero long-term debt eliminates financial leverage risk and provides balance sheet flexibility.
What are the risks of investing in CRDF?
Severe cash burn of $37.9M annually with only $17.5M cash on hand represents critical runway risk. Revenue of $593K is negligible and declining 13.2% YoY, indicating failed commercialization or clinical translation.
What is CRDF's revenue and growth?
Cardiff Oncology, Inc. reported revenue of $593.0K.
Does CRDF pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
Where can I find CRDF SEC filings?
Official SEC filings for Cardiff Oncology, Inc. (CIK: 0001213037) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRDF's EPS?
Cardiff Oncology, Inc. has a diluted EPS of $-0.69.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.